Infliximab vs rituximab
Any adverse event · adults (age 18 years and older) with refractory GPA ANCA‐associated vasculitis
The review found no eligible studies for this question.
1 finding from 1 review
- Anti‐cytokine targeted therapies for ANCA‐associated vasculitis 2020 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found